ClinicalTrials.gg
RecruitingNCT07620223PASHUpdated Jun 2, 2026

Prophylactic Antibiotics in Preventing Surgical Site Infection After Hepatobiliary Surgery in High-Resistant Settings

An interventional study of Piperacillin-tazobactam in Hepatobiliary Surgery and Prophylactic Antibiotics, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Surgical Wound Infection with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Surgical Wound Infection · China.

Planned enrollment
5th of 10
378 · median 359
Started
2026
the only one that year
No phase
9 of 14
4 open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Among the 14 studies in Surgical Wound Infection with a site in China, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 9 with no phase, and was the 13th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

4 of the 14 studies in Surgical Wound Infection with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Surgical Wound Infection with a site in China, or all of them as a file.
02

Study summary

To analyse the efficacy of different preoperative prophylactic antimicrobial regimens for perioperative infection prevention in patients undergoing hepatobiliary surgery in a high antimicrobial resistance setting.

Read the detailed description

Given the high incidence of postoperative surgical site infections (SSI) potentially attributable to bacterial antimicrobial resistance, the use of beta-lactam/beta-lactamase inhibitor combinations for prophylaxis may reduce SSI rates following hepatobiliary surgery in the current era of high antimicrobial resistance. To test this hypothesis, we propose a prospective pragmatic trial comparing piperacillin-tazobactam with the standard prophylactic regimen of cefuroxime for perioperative infection prevention in patients undergoing hepatobiliary surgery.

03

Conditions studied

  • Hepatobiliary Surgery
  • Prophylactic Antibiotics

Keywords

  • Hepatobiliary Surgery
  • Antimicrobial resistance
  • Prophylactic antibiotic
  • Surgical site infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged ≥18 years;
  • Deemed eligible for elective hepatobiliary surgery;
  • Demonstrated comprehension of the study nature and expressed willingness to comply with trial procedures;
  • Capable of providing written .

Exclusion criteria

Exclusion Criteria:

  • History of β-lactam allergy or
  • Uncontrolled preoperative infection;
  • Current or recent (within the preceding month) systemic administration;
  • Severe hepatic or renal impairment;
  • Pregnancy or lactation;
  • Concurrent enrolment in another clinical trial;
  • Any other condition deemed by the investigator to render the patient unsuitable for study participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
378 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Participants were randomized allocated to intervention group and receive piperacillin-tazobactam as prophylactic antibiotic before hepatobiliary surgery.

    Drug: Piperacillin-tazobactam

  • No intervention
    Control group

Interventions

  • DrugPiperacillin-tazobactam

    Participants were randomized allocated to intervention group and receive piperacillin-tazobactam as prophylactic antibiotic before hepatobiliary surgery. Participants in the cotrol group will receive cefuroxime for prophylactic antibiotic.

06

What researchers measure

Primary outcomes

  1. Number of participants with surgical site infection within 30 days after surgery

    The primary endpoint, overall SSI rate, is defined as superficial incisional SSI, deep incisional SSI, or organ/space SSI within the first 30 days after the operation, as defined according to the ACS NSQIP data collection operations manual.

    Time frame: 30 days after the surgery

Secondary outcomes

  1. 30-day mortality

    Time frame: 30 days after the surgery

  2. Number of Participants with Sepsis within 30 days after surgery

    Sepsis was defined according to criteria of the third international consensus of sepsis (doi: 10.1001/jama.2016.0287).

    Time frame: 30 days after the surgery

  3. Number of Participants with Postoperative bile leak or pancreas fisula

    Postoperative bile leak and pancreas fisula was assessed by the treating surgeons.

    Time frame: 30 days after surgery

  4. Postoperative hospital stay

    Time frame: Length of postoperative hospital stay from date of surgery until the date of first documented date of discharge from any cause, whichever came first, assessed up to 90 days.

  5. Number of participants with infections other than surgical site infection

    Infection was assessed by the treating surgeons.

    Time frame: Other infections occurred within 30 days after surgery.

  6. Number of Participants with unplanned readmission and secondary surgery

    Time frame: Unplanned readmission and secondary surgery within 30 days after surgery.

07

Study locations

1 of 1 sites recruiting
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
    Recruiting
    • Yao Du, Pharmacist in Charge · Contactdudu0083@126.com · +86-025-83106666-60910
    • Dayu Chen, PharmD · Principal investigator
    • Yao Du · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2028, 31 months after the start.

Of 202 non-industry interventional studies with no phase under Surgical Wound Infection, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 31 months is above that.

Counting every sponsor, half of 209 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
Jun 2, 2026
StartActual
May 24, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jan 31, 2029
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07620223
Responsible party
Chen Dayu (Pharmacist in Charge, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School) — Principal investigator
First posted
Jun 2, 2026
Start date
May 24, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Jun 2, 2026

Study contacts

Dayu Chen, Pharmacist in Charge, PharmD
Contact
cdy_pharmacy@njglyy.com
+86-025-83106666-60924

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion